



THE UNIVERSITY *of* EDINBURGH

Edinburgh Research Explorer

## Cardiovascular Effects of Urocortin 2 and Urocortin 3 in Patients with Chronic Heart Failure

**Citation for published version:**

Stirrat, CG, Venkatasubramanian, S, Pawade, T, Mitchell, AJ, Shah, AS, Lang, NN & Newby, DE 2016, 'Cardiovascular Effects of Urocortin 2 and Urocortin 3 in Patients with Chronic Heart Failure', *British Journal of Clinical Pharmacology*. <https://doi.org/10.1111/bcp.13033>

**Digital Object Identifier (DOI):**

[10.1111/bcp.13033](https://doi.org/10.1111/bcp.13033)

**Link:**

[Link to publication record in Edinburgh Research Explorer](#)

**Document Version:**

Peer reviewed version

**Published In:**

British Journal of Clinical Pharmacology

**General rights**

Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

**Take down policy**

The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact [openaccess@ed.ac.uk](mailto:openaccess@ed.ac.uk) providing details, and we will remove access to the work immediately and investigate your claim.



# Cardiovascular Effects of Urocortin 2 and Urocortin 3 in Patients with Chronic Heart Failure

## AUTHORS

Colin G Stirrat MD<sup>1\*</sup>, Sowmya Venkatasubramanian MD<sup>1\*</sup>, Tania Pawade MD<sup>1</sup>, Andrew J Mitchell MD<sup>1</sup>, Anoop S Shah MD<sup>1</sup>, Ninian N Lang PhD<sup>2</sup>, David E Newby PhD<sup>1#</sup>

<sup>1</sup>British Heart Foundation/University Centre for Cardiovascular Science, University of Edinburgh, United Kingdom

<sup>2</sup>British Heart Foundation Glasgow Cardiovascular Research Centre, Institute of Cardiovascular and Medical Sciences, University of Glasgow, United Kingdom

\*denotes joint first author

# denotes Principal Investigator

## CORRESPONDING AUTHOR

Colin G Stirrat

British Heart Foundation/University Centre for Cardiovascular Science

Room SU 305, Chancellor's Building,

University of Edinburgh,

49 Little France Crescent,

Edinburgh, EH16 4SB

Email: colin.stirrat@ed.ac.uk

Tel: 0131 242 6515 Fax: 0131 242 6379

Figures: 4

Tables: 2

Word Count: 2946

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1111/bcp.13033

All authors have completed the Unified Competing Interest form at [www.icmje.org/coi\\_disclosure.pdf](http://www.icmje.org/coi_disclosure.pdf) (available on request from the corresponding author) and declare: no support from any organisation for the submitted work; no financial relationships with any organisations that might have an interest in the submitted work in the previous 3 years; no other relationships or activities that could appear to have influenced the submitted work.

Abbreviations:

CRH – Corticotrophin-releasing hormone

CRH-R2 - Corticotrophin-releasing hormone receptor 2

NYHA – New York Heart Association

SNP – Sodium Nitroprusside

Registered clinical trial on UKCRN. ID 10749 and 13002

#### **What is already known on the subject?**

- Urocortins 2 and 3 are emerging therapies for treating heart failure.
- Urocortins 2 and 3 reduce peripheral vascular resistance and increase cardiac output in both health and disease.

#### **What this study adds?**

- This is the first direct head-to-head comparison of urocortin 2 and urocortin 3 in man.
- These data provide further evidence that urocortin 2 and urocortin 3 hold major potential for the treatment of heart failure.

## Abstract

**Aims:** Urocortin 2 and urocortin 3 may play a role in the pathophysiology of heart failure and are emerging therapeutic targets. We aimed to examine the local and systemic cardiovascular effects of urocortin 2 and urocortin 3 in healthy subjects and patients with heart failure.

**Methods:** Patients with heart failure (n=8) and age and sex-matched healthy subjects (n=8) underwent bilateral forearm arterial blood flow measurement using forearm venous occlusion plethysmography during intra-arterial infusions of urocortin 2 (3.6-36 pmol/min), urocortin 3 (360-3600 pmol/min) and substance P (2-8 pmol/min). Heart failure patients (n=9) and healthy subjects (n=7) underwent non-invasive impedance cardiography during incremental intravenous infusions of sodium nitroprusside (573-5730 pmol/kg/min), urocortin 2 (36-360 pmol/min), urocortin 3 (1.2-12 nmol/min) and saline placebo.

**Results:** Urocortin 2, urocortin 3 and substance P induced dose-dependent forearm arterial vasodilatation in both groups ( $p < 0.05$  for both) with no difference in magnitude of vasodilatation between patients and healthy subjects. During systemic intravenous infusions, urocortin 3 increased heart rate and cardiac index and reduced mean arterial pressure and peripheral vascular resistance index in both groups ( $p < 0.01$  for all). Urocortin 2 produced similar responses to urocortin 3, although increases in cardiac index and heart rate were only significant in heart failure ( $p < 0.05$ ) and healthy subjects ( $p < 0.001$ ), respectively.

**Conclusion:** Urocortins 2 and 3 cause vasodilatation, reduce peripheral vascular resistance and increase cardiac output in both health and disease. These data provide further evidence to suggest that urocortins 2 and 3 continue to hold promise for the treatment of heart failure.

**Keywords:** Cardiac; urocortin; Heart Failure; Inotrope; Vasodilator.

## Introduction

There are almost six million people living with heart failure in the USA. This comes at an annual cost to the US economy of over \$30 billion.[1] Despite many evidence-based therapies for patients with chronic heart failure, treatments for acute heart failure are limited, less well developed and have not been shown to improve clinical outcomes. Indeed the use of inotropic agents has been associated with harm.[2-4] However, the tentative but promising improvements in clinical outcome seen with serelaxin in the recent RELAX-AHF study[5] has renewed enthusiasm for the assessment of novel vasoactive mediators in this important patient group.

The urocortins are an endogenous peptidic hormone group comprising urocortin 1, urocortin 2 and urocortin 3 with vasodilator, inotropic and lusitropic effects. [6] Urocortins 2 and 3 counteract many of the effects of corticotrophin-releasing hormone (CRH), [7-10] and act on the CRH-receptor 2 (CRH-R2), a G-protein coupled receptor that is expressed abundantly in the heart and peripheral vasculature. [11,12] Urocortin 2 causes vasodilatation in healthy volunteers, augments cardiac output and reduces vascular resistance in healthy humans, patients with acute decompensated, and also chronic stable, heart failure. [13-16]

A recombinant acetate salt of urocortin 3 (JNJ-39588146 [recombinant stresscopin]), improved cardiac output whilst reducing vascular resistance in a multi-centre study of patients with chronic stable heart failure. [17] We recently demonstrated that Urocortins 2 and 3 increase forearm blood flow in young healthy volunteers. [15] To date, no clinical study has separated the regional from systemic effects of urocortins 2 and 3 in heart failure, or conducted a direct head to head comparison of their effects.

We aimed to evaluate and compare the local and systemic cardiovascular effects of urocortins 2 and 3 in patients with heart failure and healthy subjects by assessing (i) local forearm arterial blood flow using venous occlusion plethysmography, and (ii) cardiac output and vascular resistance using thoracic bioimpedance cardiography. We hypothesized that urocortins 2 and 3 would cause vasodilatation, reduced peripheral vascular resistance and increased cardiac output in both healthy subjects and patients with heart failure.

## **Methods**

Both studies were approved by the local research ethics committee (South East Scotland REC 01) and carried out in accordance with the Declaration of Helsinki. Written informed consent was obtained from all participants prior to the study.

### **Study participants**

Patients with heart failure were eligible if they were aged 18-80 years, New York Heart Association (NYHA) symptom class II-III and had echocardiographically confirmed left ventricular ejection fraction < 35% with left ventricular end diastolic diameter > 5.5 cm. Patients were required to be receiving maximally tolerated doses of angiotensin-converting enzyme inhibitor and beta-blocker therapies for at least 3 months. Healthy subjects had no significant previous medical history and were on no regular medications. Exclusion criteria for both groups included systolic blood pressure >190 mmHg or <90 mmHg, hemodynamically significant valvular heart disease and other severe or significant comorbidities including bleeding diathesis, renal or hepatic failure, anemia or recent infective/inflammatory conditions. Women of child bearing potential were also excluded.

### ***Protocol A: Local vascular study***

This was a randomized study (Figure 1a) of 8 patients with heart failure and 8 age and sex-matched healthy subjects. Subjects attended once each to receive incremental intra-arterial infusions of urocortin 2 (3.6, 12, 36 pmol/min, molecular weight 4450.3g/mol) urocortin 3 (360, 1200, 3600 pmol/min, molecular weight 4137.9g/mol) and substance P (2, 4, 8 pmol/min [control endothelium-dependent vasodilator]) for six min at each dose with a 30 min washout period between agents.

Forearm venous occlusion plethysmography studies were performed with the subject lying supine, in a quiet, temperature-controlled room (22-25°C). Participants fasted for 4 hours prior to the study and refrained from alcohol and caffeine for 24 hours prior to the study. Venous cannulae (17G) were inserted into large subcutaneous veins in the antecubital fossae of both arms at the start of the study to facilitate periodic venous sampling. Heart rate and blood pressure were monitored at regular intervals throughout the study with a semi-automated oscillometric sphygmomanometer (Omron 705IT). Participants underwent brachial artery cannulation of the non-dominant forearm with a 27 standard wire-gauge steel needle for agent infusion. Forearm blood flow was measured in the infused and non-infused forearms using bilateral venous occlusion plethysmography as described previously. [18,19]

### ***Protocol B: Systemic Study***

This was a randomized, double-blind, placebo controlled cross-over study (Figure 1b). Three patients with heart failure and three volunteers participants were involved in both studies. Patients with heart failure (n=9) and healthy subjects (n=7) were recruited. Participants had venous cannulae inserted into both antecubital fossae, and attended on two occasions, receiving intravenous infusions of saline (placebo) or SNP (573, 1909, 5730 pmol/kg/min) followed by either urocortin 2 (36, 108, 360 pmol/min) or urocortin 3 (1.2, 3.6, 12 nmol/min).

On the second visit, participants received the 2 remaining agents not administered on visit 1. Each agent was given in 3 ascending doses for 10 min at each dose. A one-hour saline washout was given between agents and a further 30 min of saline washout was administered after the cessation of the second agent.

#### *Hemodynamic Monitoring*

Hemodynamic measurements were recorded throughout the study. Cardiac output, blood pressure and stroke volume were recorded using non-invasive thoracic impedance cardiography (NCCOM3-R7, BioMed, CA, USA or Cardioscreen 1000, Medis, Germany) and oscillometric sphygmomanometry (Omron HEM-705CP, Omron, Matsusaka, Japan). Values were indexed to body surface area where appropriate and peripheral vascular resistance index was calculated using recorded measurements ( $PVRI = MAP/CI$ ).

#### *Safety:*

Study stopping criteria were in place to ensure participant safety. Criteria included a drop in diastolic blood pressure of  $>25$  mmHg, fall in heart rate below 50 bpm or rise above 120 bpm, at the request of the participant, attending nurse or the attending physician.

#### *Venous sampling*

Baseline blood samples were drawn for assessment of full blood count, renal function, glucose and cholesterol concentrations at the start of each study. The local clinical biochemistry and hematology reference laboratories performed analysis.

### *Data analysis and Statistics*

Data were collected in a double blind fashion for both studies. Data were analysed, where appropriate, by analysis of variance (ANOVA; one-way and two-way with repeated measures where appropriate). All results in figures are expressed as mean  $\pm$  SEM. All statistical analysis was performed with GraphPad Prism, version 6 (GraphPad Software, San Diego, CA). Statistical significance was taken as two-sided  $P < 0.05$ .

## **RESULTS**

Patients with heart failure and healthy subjects recruited were predominantly male and middle-aged. Heart failure patients had greater BMI compared to healthy subjects. (Participant characteristics are shown in Table 1). Patients with heart failure were receiving maintenance heart failure therapy. Patients and volunteers were age and sex matched in Protocol A, and age matched alone in protocol B. Three patients with heart failure and three volunteers participants were recruited to both studies.

### *Protocol A – Vascular Study*

The intra-brachial infusion of all three drugs was well tolerated with no adverse effects. Intra-brachial infusion of urocortin 2 and 3 produced localised, self-limiting forearm flushing and some facial flushing in both groups of participants as noted in previous studies. [15]

Urocortin 2, urocortin 3 and substance P all evoked dose-dependent forearm arterial vasodilatation in both participant groups (mean changes across the 3 doses [95%CI] from baseline as follows; Urocortin 2: +60% [9-111]  $p < 0.05$ , +72% [21-123]  $p < 0.01$ ; Urocortin 3: +167% [100-237]  $p < 0.0001$ , +151% [82-219]  $p < 0.0001$ ; Substance P: +227% [130-326]  $p < 0.0001$ , +155% [57-253]  $p < 0.001$  for healthy controls and heart failure patients

respectively; Figure 2a). There were no significant differences in changes in forearm blood flow between heart failure patients and healthy subjects (urocortin 2; +12% [-40 to 63%]  $p=0.84$ , urocortin 3; -18% [-86 to +50%],  $p=0.80$ ; Substance P; -72% [-170-+26%]  $p=0.19$ ).

Blood pressure and heart rate remained unchanged in both groups in response to urocortin 2 and substance P. At the highest dose, urocortin 3 induced a transient tachycardia compared to baseline in both groups (heart failure - +14.9bpm [20.9 to 8.9], healthy volunteers - +21.3mmHg [27.3 to 15.3] both  $p<0.0001$ ) that was accompanied by a drop in systolic (-17.4mmHg [-7.9 to -26.9],  $p<0.0001$ ) and diastolic blood pressure in patients with heart failure (-8.4mmHg [-3.5 to -13.3],  $p<0.001$ ) and a drop in diastolic blood pressure alone in healthy subjects (-12.4mmHg [-7.5 to -17.3],  $p<0.0001$ , Figure 2b). Non-infused forearm blood flow remained unchanged throughout the study (data not shown).

#### *Protocol B – Systemic Study*

Participants displayed hypotension at the higher doses of SNP initially administered in the study (17.2 nmol/kg/min), frequently reaching study-stopping criteria. A dose reduction to SNP (maximum dose of 5730 pmol/kg/min) was made after 2 healthy subjects completed the study. For the urocortins, hypotension reaching study-stopping criteria was met in 1 heart failure patient for urocortin 2, and 2 heart failure patients and 1 healthy subject for urocortin 3. Participants described dose-dependent symptoms of tachycardia and a warm sensation with both urocortins, but there were no significant adverse events attributable to either urocortin 2 or urocortin 3. Full blood count and serum biochemistry was unchanged between the two study visits (Table 1).

Urocortin 2 had no significant effect on cardiac index in healthy subjects and heart rate in heart failure patients when compared to saline placebo ( $p>0.05$  for both, see Figure 3 and

Table 2 for results). Otherwise urocortin 2 and urocortin 3 increased cardiac index and heart rate, and reduced mean arterial pressure and peripheral vascular resistance index in both patients with heart failure and healthy subjects ( $p < 0.05$  for all). There was no effect of either urocortin 2 or urocortin 3 on stroke volume ( $p > 0.05$  for both).

At the doses used, urocortin 3 caused greater mean increases than urocortin 2 in cardiac index (+13.4 [+4.1 to +22.6],  $p < 0.01$ ) and heart rate (+11.0 [+2.9 to +19.2],  $p < 0.01$ ), and greater mean reductions in mean arterial pressure (+4.4 [0.0 to +8.7],  $p < 0.05$ ) and peripheral vascular resistance index (+11.2 [2.2 to +20.1],  $p < 0.01$ ) in patients with heart failure. No such haemodynamic differences existed between urocortin 2 and urocortin 3 in healthy subjects. No haemodynamic differences existed between participant groups for both urocortin 2 and urocortin 3 ( $p > 0.05$  for all). Following cessation of the intravenous infusions, hemodynamic variables returned to baseline after 40–60 min (for example, cardiac index, Figure 4). Over the infusion and washout period, urocortin 3 again caused a greater increase in cardiac output ( $p < 0.0001$ ) than urocortin 2 in patients with heart failure but not in healthy subjects ( $p = 0.48$ ).

## Discussion

For the first time, we report the local vascular and systemic effects of urocortins in both patients with heart failure and healthy subjects. We demonstrate that both urocortin 2 and urocortin 3 increase cardiac index and reduce peripheral vascular resistance, and their parenteral administration is feasible, safe and well tolerated. We conclude this hemodynamic profile suggests that urocortins 2 and 3 hold major potential for the treatment of acute heart failure.

Forearm venous occlusion plethysmography combined with intra-arterial cannulation allows the assessment of local, sub-systemic vasomotor effects of peptides without exerting a systemic response. This is particularly useful in the study of novel compounds, such as urocortin 2 and urocortin 3. We have previously demonstrated that urocortin 2 and 3 cause vasodilatation in healthy subjects and that is in part mediated by endothelium-dependent factors such as nitric oxide and endothelium derived hyperpolarizing factor [15]. Impaired endothelial function is a recognized feature and an independent predictor of adverse outcome in patients with heart failure.[20-24] There is therefore a theoretical concern that urocortin would be less effective in patients with heart failure because of this concomitant endothelial dysfunction. However, we demonstrate that urocortin 2 and urocortin 3 evoked normal forearm arterial vasodilatory responses in our patients with heart failure. This suggests that either endothelial dysfunction does not have a meaningful impact on the actions of urocortin or our subjects did not have significant endothelial dysfunction. Interestingly, our patients did not demonstrate impaired substance P induced vasodilatation suggesting preserved endothelial function. This may reflect that the patients studied had stable heart failure symptoms and were well-treated and receiving optimal medical therapy. Whether similar findings would be observed in patients with decompensated heart failure remains to be established.

During local intra-arterial infusions of the urocortins, we were not anticipating observing any major changes in hemodynamic variables in either group. However, we found dose-related increases in heart rate and falls in diastolic blood pressure, especially with urocortin 3 in healthy subjects. This suggests that at the doses used here, we had systemic spill over of urocortin such that we achieved vasoactive blood concentrations outwith the forearm. The doses where systemic systemic spill over was seen helped guide the dosing regime used in

protocol B. We have seen systemic spill over previously with other compounds such as substance P [25], and this is heralded by systemic flushing and rises in the contralateral non-infused forearm blood flow. However, here we observed no change in contralateral non-infused forearm blood flow although subjects did develop some skin flushing. This suggests that other vascular beds, such as the dermal and splanchnic circulation, are more sensitive to the actions of the urocortins than the forearm circulation. The increase in heart rate at the highest dose of urocortin 3 was less pronounced in patients with heart failure, and this was likely due to concomitant beta-blocker therapy. Furthermore the associated lower systolic and diastolic blood pressures in this group may be explained by a relative lack of compensatory tachycardia response to vasodilatation in these patients.

During systemic intravenous infusions, we observed increases in cardiac output with both urocortins. This increase in cardiac output is likely to occur in response to the systemic vasodilatation induced by the urocortins. Although there was no change in stroke volume for either urocortin, this is not a direct measurement of inotropy, and we cannot exclude a direct inotropic effect of urocortin on the heart, as previously seen with Urocortin 2 in rodents. [26] At the doses we administered, urocortin 3 exerted more marked hemodynamic effects than urocortin 2 in patients but not healthy subjects. This may reflect the differences in doses we employed, but may also reflect important differences between these two agents. This needs further exploration to determine which urocortin subtype is the most promising for clinical therapeutic development.

Differences in biological effects between the urocortins can be explained by the structural differences that exist between the two agents, generating conformational changes in the G protein coupled receptor, in turn altering secondary messenger systems that are responsible for creating the biological effects seen. However it may not be this simple and there may be

other systems involved. Promising preclinical studies suggest a role for the urocortins in the inhibition of cardiac sympathetic nerve activity [SNA] [27,28], often overactive in patients with heart failure. Although Ucn2 has been reported to increase skeletal muscle SNA in humans, [29] this should not necessarily be seen as a discrepant finding as SNA responses typically are regionally differentiated.

Increases in heart rate have not been reported in recent studies with urocortin 2/stresscopin, [16,17] however higher doses of urocortin 2, [14] comparable to the doses we have used here, saw similar increases in heart rate.

There may be concern regarding the clinical use of a heart failure therapy that is both positively chronotropic and inotropic. This combination of effects might predispose to increased myocardial oxygen consumption and potential arrhythmia, particularly in patients with coronary artery disease. We observed no episodes of arrhythmia or adverse effects in our study, and indeed urocortin 2 has been shown to have anti-arrhythmic effects that would be hugely beneficial in treating this group of patients. [30] [31] However, our infusions were brief, and adverse effects may be seen with longer infusions or in those patients with decompensated heart failure. In addition, avoidance of significant hypotension remains an important consideration, especially in patients with already low perfusion pressure or renal impairment. Results from our study suggest that dose titration during administration may be needed to optimize cardiac output and vasodilatory responses, whilst avoiding the unwanted effects of significant tachycardia or hypotension.

### **Study Limitations**

This study included only patients with stable heart failure who were prescribed evidence-based heart failure therapy that may have affected the response of these agents. However, there was no evidence of diminished effect with concomitant medical therapy in patients with

heart failure. We did not include patients with acute decompensated heart failure, but we did compare to healthy control subjects, not used in a similar sized study with urocortin 2.[14] Although our results cannot be extrapolated to the setting of acute heart failure, there appears to be no reason why the beneficial effects seen in this study cannot be replicated in the acute heart failure setting provided an appropriate, controlled dosing regime is used. Furthermore studies using Urocortin 2, and derivatives thereof, in the acute setting have already been carried out successfully. There does however remain a clear need for urocortin 3 to be trialed in this group of patients.

We observed increases in cardiac index in protocol B, but it should be reinforced that this study was not designed to compare the relative contributions of chronotropy, inotropy and vasodilatation to the changes in cardiac index we recorded. Invasive studies would be required for this. Furthermore, the molar concentrations of urocortin 2 and urocortin 3 at each dose were different, and differences in efficacy may reflect the differences in dose used, and not true differences in potency.

Finally although there was no change in stroke volume for either agent, we did not conduct invasive hemodynamic monitoring which would be required for assessment of true inotropy, and also useful for assessment of pulmonary capillary wedge pressure (PCWP). Surprisingly two recent studies did not detect a statistically significant reduction in PCWP in patients with heart failure with either urocortin 2/stresscopin, [16,17] however a clear trend toward a reduction in PCWP was seen in both studies.

#### Conclusion:

We demonstrate that both urocortin 2 and urocortin 3 increase cardiac index and reduce peripheral vascular resistance. Their parenteral administration was feasible, safe and well tolerated. We conclude that these data provide further evidence suggesting urocortin 2 and urocortin 3 continue to hold promise for the treatment of heart failure.


## References:

1. Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, de Ferranti S, Després J-P, Fullerton HJ, Howard VJ, Huffman MD, Judd SE, Kissela BM, Lackland DT, Lichtman JH, Lisabeth LD, Liu S, Mackey RH, Matchar DB, McGuire DK, Mohler ER, Moy CS, Muntner P, Mussolino ME, Nasir K, Neumar RW, Nichol G, Palaniappan L, Pandey DK, Reeves MJ, Rodriguez CJ, Sorlie PD, Stein J, Towfighi A, Turan TN, Virani SS, Willey JZ, Woo D, Yeh RW, Turner MB, American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics--2015 update: a report from the American Heart Association. *Circulation*. Lippincott Williams & Wilkins; 2015 Jan 27;131(4):e29–322.
2. Elkayam U, Tasissa G, Binanay C, Stevenson LW, Gheorghiade M, Warnica JW, Young JB, Rayburn BK, Rogers JG, DeMarco T, Leier CV. Use and impact of inotropes and vasodilator therapy in hospitalized patients with severe heart failure. *American Heart Journal*. 2007 Jan;153(1):98–104.
3. Felker GM, Benza RL, Chandler AB, Leimberger JD, Cuffe MS, Califf RM, Gheorghiade M, O'Connor CM, Investigators O-C. Heart failure etiology and response to milrinone in decompensated heart failure - Results from the OPTIME-CHF study. *JAC*. 2003;41(6):997–1003.
4. Cuffe MS, Califf RM, Adams KF, Benza R, Bourge R, Colucci WS, Massie BM, O'Connor CM, Pina I, Quigg R, Silver MA, Georghiade M, Investigators O-C. Short-term intravenous milrinone for acute exacerbation of chronic heart failure - A randomized controlled trial. *JAMA*. American Medical Association; 2002;287(12):1541–7.
5. Teerlink JR, Cotter G, Davison BA, Felker GM, Filippatos G, Greenberg BH, Ponikowski P, Unemori E, Voors AA, Adams KF, Dorobantu MI, Grinfeld LR, Jondeau G, Marmor A, Masip J, Pang PS, Werdan K, Teichman SL, Trapani A, Bush CA, Saini R, Schumacher C, Severin TM, Metra M, RELAXin in Acute Heart Failure (RELAX-AHF) Investigators. Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial. *Lancet*. 2013 Jan 5;381(9860):29–39.
6. Venkatasubramanian S, Newby DE, Lang NN. Urocortins in heart failure. *Biochem Pharmacol*. 2010;80(3):289–96.
7. Rademaker MT, Charles CJ, Espiner EA, Fisher S, Frampton CM, Kirkpatrick CMJ, Lainchbury JG, Nicholls MG, Richards AM, Vale WW. Beneficial hemodynamic, endocrine, and renal effects of urocortin in experimental heart failure: comparison with normal sheep. *JAC*. 2002 Oct 16;40(8):1495–505.
8. Rademaker MT, Cameron VA, Charles CJ, Richards AM. Integrated hemodynamic, hormonal, and renal actions of urocortin 2 in normal and paced sheep: beneficial effects in heart failure. *Circulation*. Lippincott Williams & Wilkins; 2005 Dec 6;112(23):3624–32.

9. Rademaker MT, Cameron VA, Charles CJ, Richards AM. Urocortin 3: haemodynamic, hormonal, and renal effects in experimental heart failure. *European Heart Journal*. 2006 Sep;27(17):2088–98.
10. Takahashi K, Totsune K, Murakami O, Saruta M, Nakabayashi M, Suzuki T, Sasano H, Shibahara S. Expression of urocortin III/stresscopin in human heart and kidney. *The Journal of Clinical Endocrinology & Metabolism*. Endocrine Society; 2004 Apr;89(4):1897–903.
11. Wiley KE, Davenport AP. CRF2 receptors are highly expressed in the human cardiovascular system and their cognate ligands urocortins 2 and 3 are potent vasodilators. *British Journal of Pharmacology*. Blackwell Publishing Ltd; 2004 Oct 1;143(4):508–14.
12. Kimura Y. Expression of Urocortin and Corticotropin-Releasing Factor Receptor Subtypes in the Human Heart. *The Journal of Clinical Endocrinology & Metabolism*. Endocrine Society; 2002 Jan 1;87(1):340–6.
13. Davis ME, Pemberton CJ, Yandle TG, Fisher SF, Lainchbury JG, Frampton CM, Rademaker MT, Richards AM. Urocortin 2 infusion in healthy humans: hemodynamic, neurohormonal, and renal responses. *J Am Coll Cardiol*. 2007 Jan 30;49(4):461–71.
14. Davis ME, Pemberton CJ, Yandle TG, Fisher SF, Lainchbury JG, Frampton CM, Rademaker MT, Richards M. Urocortin 2 infusion in human heart failure. *European Heart Journal*. 2007 Nov;28(21):2589–97.
15. Venkatasubramanian S, Griffiths ME, McLean SG, Miller MR, Luo R, Lang NN, Newby DE. Vascular effects of urocortins 2 and 3 in healthy volunteers. *J Am Heart Assoc*. Lippincott Williams & Wilkins; 2013 Feb;2(1):e004267–7.
16. Chan WYW, Frampton CM, Crozier IG, Troughton RW, Richards AM. Urocortin-2 infusion in acute decompensated heart failure: findings from the UNICORN study (urocortin-2 in the treatment of acute heart failure as an adjunct over conventional therapy). *JACC Heart Fail*. 2013 Oct;1(5):433–41.
17. Gheorghide M, Greene SJ, Ponikowski P, Maggioni AP, Korewicki J, Macarie C, Metra M, Grzybowski J, Bubenek-Turconi S-I, Radziszewski W, Olson A, Bueno OF, Ghosh A, Deckelbaum LI, Li LY, Patel AR, Koester A, Konstam MA. Haemodynamic effects, safety, and pharmacokinetics of human stresscopin in heart failure with reduced ejection fraction. *Eur J Heart Fail*. 2013 Jun;15(6):679–89.
18. Newby DE, Wright RA, Ludlam CA, Fox KA, Boon NA, Webb DJ. An in vivo model for the assessment of acute fibrinolytic capacity of the endothelium. *Thromb Haemost*. 1997 Oct;78(4):1242–8.
19. Newby DE, Wright RA, Labinjoh C, Ludlam CA, Fox KA, Boon NA, Webb DJ. Endothelial dysfunction, impaired endogenous fibrinolysis, and cigarette smoking: a mechanism for arterial thrombosis and myocardial infarction. *Circulation*. Lippincott Williams & Wilkins; 1999 Mar 23;99(11):1411–5.


20. Katz SD, Biasucci L, Sabba C, Strom JA, Jondeau G, Galvao M, Solomon S, Nikolic SD, Forman R, LeJemtel TH. Impaired endothelium-mediated vasodilation in the peripheral vasculature of patients with congestive heart failure. *JAC. Journal of the American College of Cardiology*; 1992 Apr;19(5):918–25.
21. Kubo SH, Rector TS, Bank AJ, Williams RE, Heifetz SM. Endothelium-dependent vasodilation is attenuated in patients with heart failure. *Circulation*. 1991 Oct;84(4):1589–96.
22. Yang O, Li J, Kong J. *The Endothelium as a Target for the Treatment of Heart Failure. Cell Biochem Biophys*. Springer US; 2015 Jan 24;:1–6.
23. de Berrazueta JR, Guerra-Ruiz A, García-Unzueta MT, Toca GM, Laso RS, de Adana MS, Martín MAC, Cobo M, Llorca J. Endothelial dysfunction, measured by reactive hyperaemia using strain-gauge plethysmography, is an independent predictor of adverse outcome in heart failure. *Eur J Heart Fail*. 2010 May;12(5):477–83.
24. Takishima I, Nakamura T, Hirano M, Kitta Y, Kobayashi T, Fujioka D, Saito Y, Watanabe K, Watanabe Y, Mishina H, Obata J-E, Kawabata K-I, Tamaru S, Kugiyama K. Predictive value of serial assessment of endothelial function in chronic heart failure. *International Journal of Cardiology*. 2012 Jul 26;158(3):417–22.
25. Newby DE, Sciberras DG, Mendel CM, Gertz BJ, Boon NA, Webb DJ. Intra-arterial substance P mediated vasodilatation in the human forearm: pharmacology, reproducibility and tolerability. *Br J Clin Pharmacol*. 1997 May;43(5):493–9.
26. Bale TL, Hoshijima M, Gu Y, Dalton N, Anderson KR, Lee KF, Rivier J, Chien KR, Vale WW, Peterson KL. The cardiovascular physiologic actions of urocortin II: Acute effects in murine heart failure. *Proc Natl Acad Sci USA. National Acad Sciences*; 2004;101(10):3697–702.
27. Charles CJ, Jardine DL, Rademaker MT, Richards AM. Urocortin 2 induces potent long-lasting inhibition of cardiac sympathetic drive despite baroreflex activation in conscious sheep. *J Endocrinol*. 2010 Feb;204(2):181–9.
28. Charles CJ, Jardine DL, Rademaker MT, Richards AM. Urocortin 3 inhibits cardiac sympathetic nerve activity in conscious sheep. *J Cardiovasc Pharmacol*. 2011 Oct;58(4):418–23.
29. Chan WYW, Charles CJ, Frampton CM, Richards AM, Crozier IG, Troughton RW, Jardine DL. Human Muscle Sympathetic Nerve Responses to Urocortin-2 in Health and Stable Heart Failure. *Clin Exp Pharmacol Physiol*. 2015 Jul 14.
30. Meili-Butz S, Bühler K, John D, Buser P, Vale WW, Peterson KL, Brink M, Dieterle T. Acute effects of urocortin 2 on cardiac function and propensity for arrhythmias in an animal model of hypertension-induced left ventricular hypertrophy and heart failure. *Eur J Heart Fail*. 2010 Aug;12(8):797–804.
31. Liu C-N, Yang C, Liu X-Y, Li S. In vivo protective effects of urocortin on ischemia-reperfusion injury in rat heart via free radical mechanisms. *Can J Physiol Pharmacol*. 2005 Jun;83(6):459–65.

e




**Figure 1a** : Schematic representation of study protocol A – vascular study.

Accepted




**Figure 1b:** Schematic representation of study protocol B – systemic study.

Accepted




### A – Forearm Blood Flow



### B – Systemic Haemodynamic Responses



**Figure 2:** Haemodynamic responses during local administration of urocortin 2, urocortin 3 and Substance P (Protocol A).

**A:** Percentage change in forearm arterial blood flow to urocortin 2 (3.6-36 pmol/min), urocortin 3 (360-3600 pmol/min) and substance P (2-8 pmol/min) in patients with heart failure (red) and in healthy subjects (black). **B:** Non-invasive systemic hemodynamic responses to intra-arterial urocortin 2 (red), urocortin 3 (blue) and substance P (green) in healthy subjects (left) and patients with heart failure (right). (\*\*\*\*= $p < 0.0001$ , \*\*= $p < 0.01$ , \*= $p < 0.05$ ).



**Figure 3:** Changes in hemodynamic responses from baseline following systemic infusion (Protocol B).

Hemodynamic responses to infusions of urocartin 2, urocartin 3 and SNP in healthy subjects (black) and patients with heart failure (red) at Doses 1-3 (D1-D3). \* represents significant differences to saline placebo (not shown) across the 3 doses (see Table 2). ^ represents significant differences between participant groups. (\*\*\*\*= $p < 0.0001$ , \*\*\*= $p < 0.001$ , \*\*= $p < 0.01$ , \*= $p < 0.05$ ; ^^= $p < 0.01$ ).



**Figure 4:** Duration of hemodynamic response (mins) to intravenous urocortin 2 and urocortin 3 (Protocol B).

Effects of urocortin 2 (red) and urocortin 3 (blue) last 40-60 minutes after cessation of Dose 3 (D3) before returning to baseline. At the doses used, urocortin 3 caused a greater increase in cardiac output compared to urocortin 2 in patients with heart failure ( $p < 0.0001$ ) but not healthy subjects ( $p = 0.48$ ).

Accepted

Table 1: Participant Characteristics for Protocol A and B.

	<u>Protocol A</u>			<u>Protocol B</u>		
	<u>Heart failure patients (n=8)</u>	<u>Healthy Subjects (n=8)</u>		<u>Heart failure patients (n=9)</u>	<u>Healthy Subjects (n=7)</u>	
<u>Age</u>	<u>55.5</u> <u>[52.25-67]</u>	<u>57</u> [53- <u>65.75]</u>	<u>p=0.84</u>	<u>58</u> [50-66.5]	<u>58</u> [45-66]	<u>p=0.56</u>
<u>BMI</u>	<u>30±5.4</u>	<u>25.1±2.3</u>	<u>p=0.03</u>	<u>32.2±4.3</u>	<u>25.9±1.9</u>	<u>p=0.003</u>
<u>Sex</u>	<u>5m, 3f</u>	<u>5m, 3f</u>		<u>7m, 2f</u>	<u>4m, 3f</u>	
<u>ACEi/ ARB</u>	<u>8 (100)</u>	<u>n/a</u>		<u>9 (100)</u>	<u>n/a</u>	
<u>BB</u>	<u>6 (75)</u>	<u>n/a</u>		<u>7 (78)</u>	<u>n/a</u>	
<u>MRA</u>	<u>5 (63)</u>	<u>n/a</u>		<u>8 (89)</u>	<u>n/a</u>	
<u>Digoxin</u>	<u>1 (13)</u>	<u>n/a</u>		<u>4 (44)</u>	<u>n/a</u>	
<u>Loop diuretic</u>	<u>6 (75)</u>	<u>n/a</u>		<u>6 (67)</u>	<u>n/a</u>	
<u>Haemoglobin (visit 1 vs visit 2, g/L)</u>	<u>n/a</u>	<u>n/a</u>		<u>136.0±14.46</u> <u>vs</u> <u>133.0±14.96</u> <u>(p&gt;0.99)</u>	<u>143.7±7.111</u> <u>vs</u> <u>135.3±8.524</u> <u>(p&gt;0.99)</u>	
<u>Creatinine (visit 1 vs visit 2, µmol/L)</u>	<u>n/a</u>	<u>n/a</u>		<u>109.8±39.66</u> <u>vs</u> <u>116.3±74.95</u> <u>(p&gt;0.99)</u>	<u>75.29±8.635</u> <u>vs</u> <u>72.67±7.840</u> <u>(p&gt;0.99)</u>	

N (%), mean±SD, median [interquartile range]

Table 2: Results of Systemic Infusion of Urocortin 2 and 3.

Healthy Volunteers	Urocortin 2	Urocortin 3	SNP
Cardiac Index	+11.9 [-3.1 to +26.9] p=0.17	+25.4 [+9.8 to +41.0]***	+21.7 [+5.5 to +37.8]**
Heart Rate	+17.2 [+7.2 to +27.1]***	+25.0 [+14.7 to +35.4]****	+29.0 [+18.4 to +39.8]****
MAP	-8.0 [-2.6 to -13.5]**	-10.8 [-5.1 to -16.4]****	-13.0 [-7.2 to -18.8]****
SV	-3.7 [-13.8 to +6.4] p=0.77	-6.3 [-16.9 to +4.2] p=0.40	-6.8 [-17.4 to +3.9] p=0.35
PVRI	-17.6 [-3.5 to -31.7]**	-23.1 [-8.4 to -37.8]***	-22.1 [-6.9 to -37.3]**
Heart Failure			
Cardiac Index	+10.1 [+1.0 to +19.3] *	+23.5 [+14.3 to +32.7]****	+14.2 [+3.8 to +24.7]**
Heart Rate	+7.1 [-0.8 to +15.0] p=0.1	+18.1 [+10.0 to +26.3]****	+7.4 [-1.8 to +16.6] p=0.16
MAP	-4.8 [-0.5 to -9.0]*	-9.1 [-4.8 to -13.5]****	-13.6 [-8.7 to -18.5]****
SV	+2.7 [-2.4 to +7.8] p=0.51	+4.3 [-0.9 to +9.5] p=0.14	+0.7 [-4.8 to +6.3] p=0.99
PVRI	-14.0 [-5.3 to -22.7] ***	-25.2 [-16.2 to -34.2]****	-22.1 [-12.2 to -32.0]****

Mean difference [95%CI] of each agent with saline placebo across the 3 administered doses.

\* represents significant differences with placebo. (\*\*\*\*=p<0.0001, \*\*\*=p<0.001, \*\*=p<0.01, \*=p<0.05).